Randall A. Oyer, MD, explains how ACCC is utilizing the data on genetics presented at the 2018 Annual Meeting Annual…
Browsing: General
Ivo Abraham, PhD, RN, talks about biosimilars that are approved or close to approval at Annual Meeting 2018.
Ghassan Abou-Alfa, MD, MBA, explains the shortcomings of the RECIST study in measuring efficacy in hepatocellular carcinoma (HCC) patients at…
Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation Trust, London, UK gives his highlights from the the…
The 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, proved to be an exciting…
Jennie Crews, MD, MMM, FACP, talks about key initiatives for the ACCC Immuno-Oncology Institute at Annual Meeting 2018
Ghassan Abou-Alfa, MD, MBA, explains the outcomes of the CELESTIAL study from Annual Meeting 2018.
Ivo Abraham, PhD, RN, shares his thoughts on demonstrating the value of cancer care in today’s oncology landscape at Annual…
Jennie Crews, MD, MMM, FACP, discusses the mission of the ACCC Immuno-Oncology Institute at Annual Meeting 2018.
Ghassan Abou-Alfa, MD, MBA, explains how immunotherapies should be combined with TKIs at Annual Meeting 2018.
Ivo Abraham, PhD, RN, explains the key characteristics of a biosimilar at Annual Meeting 2018.
Jennie Crews, MD, MMM, FACP, talks about how community oncology is interpreting and incorporating biomarkers into their immuno-oncology therapeutic choices
Ghassan Abou-Alfa, MD, MBA, talks about the latest in systemic therapy for advanced hepatocellular carcinoma (HCC) at the 2018 Annual…
Although clinical trials provide us with an abundance of useful data, some of this may not be optimal for application…
Mick Peake, MD, of the University of Leicester, Leicester, UK, discusses the Collaboration for Oncology Data in Europe (CODE); an…
In this video, Mick Peake, MD, of the University of Leicester, Leicester, UK, notes the importance of collating information regarding…
Joan Schiller, MD, shares the validity of Tumor Mutation Burden (TMB) as a biomarker at Annual Meeting 2018.
Joan Schiller, MD, shares Keynote trials & the influence on choice of therapy from Annual Meeting 2018.
Treatment options for gynecological cancers have become more effective and diverse in the last few decades. In this video, Marcia…
Speaking at the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Dr Woolmore, Initiative Lead, Collaboration for Oncology Data…
Immunotherapy has huge potential for treating a wide variety of cancer types. In this video, recorded at the UK Oncology…
The RANGO project aims to create a database for rare gynecological tumors in order to facilitate improved disease understanding and…
Much of the focus for immunotherapy research is on the cancers for which it works best, such as Hodgkin lymphoma…
Collaboration for Oncology Data in Europe (CODE) is a collaborative network that aims to promote the sharing of research data…
Quality of life and symptom data are essential for informing treatment plans as a clinician, as Esther Oliva, MD, of…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Fabio Guolo, MD, of…
The European Hematology Association (EHA) Scientific Working Group on Aging and Hematology released a new edition about geriatric oncology. Here,…
Chimeric antigen receptor (CAR) T-cells have been a key focus in cancer research over recent years; however, T-cells are not…
Bobby Green, MD, explains Flatiron’s clinico-genomic database helping shed light on the cost-effectiveness of next-generation sequencing.
Bobby Green, MD, explains Flatirons clinico-genomic database and how it may be used to direct treatments.
Roy S. Herbst, MD, PhD, talks about Exciting developments from the 2018 Annual Meeting.
Bobby Green, MD, shares what people will most likely be talking about from the 2018 Annual Meeting.
Edgardo S. Santos, MD, FACP, shares exciting developments coming out of the 2018 Annual Meeting
Patient-reported outcomes (PROs) give a greater insight into the lives of patients and their perspectives on the treatment received. Here,…
Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Paul Richardson, MD,…
Willem Ouwehand, MD, PhD, of the University of Cambridge, Cambridge, UK, discusses non-malignant hematology, particularly rare inherited disorders of hematopoietic…
HaemSTAR is a network of clinical hematology registrars within the UK that aims to promote clinical research in non-malignant hematology.…
A large proportion of gynecological tumors are classed as rare tumors because of their variable morphologies and pathologies. We interviewed…
In this Virtual Patient Case, renown clinical expert Dr. Martyn Caplin utilizes a follow-up clinical scenario to elucidate the latest…
In this Virtual Patient Case, renown clinical expert Dr. Martyn Caplin utilizes a clinical scenario to elucidate the latest advances…
Collaboration for Oncology Data in Europe (CODE) is an alliance that brings together patient associations, charities and treatment centers in…
The integration of scientific research into clinical practice is one of the many challenges healthcare professionals face. Here, Mariam Jamal-Hanj,…
Voluntary, non-remunerated blood donations are uncommon in developing countries and ethnic minority populations. Kenneth Charles, MBBS, FRCP, FRCPath(Haem), from the…
At the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Steve Williamson, from Northumbria NHS Foundation Trust, Newcastle upon…
Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held…
The next 4 years are going to be exciting and productive for transplant research across a broad range of hematological…
In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of…
Venous thromboembolism (VTE) effects 20% of all cancer patients. In this interview with Cihan Ay, MD, from the Medical University…
Physicians may encounter difficulties integrating proton beam therapy amongst existing radiotherapy options. Here, Neil Burnet, MA, MBBChir, FRCR, MD, of…
The introduction of proton beam therapy has brought with it a multitude of implications, which Neil Burnet, MA, MBBChir, FRCR,…